Savior Lifetec

Savior Lifetec Net Margin

The Net Profit Margin of Savior Lifetec (4167.TWO) as of Oct 25, 2026 is 44.72 %. In the previous year, Net Profit Margin was 14.98 % — a change of 198.52% (higher).

Net Margin

44.72 %

YoY

198.52%

Last updated:

Net Profit Margin of Savior Lifetec is 2025 44.72 % . Net Profit Margin of Savior Lifetec was 2024 14.98 % . It decreases by 198.52% higher compared to the previous year.

For Savior Lifetec, the net margin of 44.7% is up versus -0.3% a few years ago.

The Savior Lifetec Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-32.55 TWD
Jan 1, 2019
-3.34 TWD
Jan 1, 2020
13.73 TWD
Jan 1, 2021
-0.27 TWD
Jan 1, 2022
1.63 TWD
Jan 1, 2023
2.86 TWD
Jan 1, 2024
14.98 TWD
Jan 1, 2025
44.72 TWD
The Savior Lifetec Net Margin history
YEARNet MarginYoY
44.72 %+198.52%
14.98 %+423.98%
2.86 %+75.55%
1.63 %-696.31%
-0.27 %-101.99%
13.73 %-511.15%
-3.34 %-89.74%
-32.55 %-2,464.54%
1.38 %-110.15%
-13.56 %-69.24%
-44.06 %+26.18%
-34.92 %+15,179.42%
-0.23 %-57.71%
-0.54 %+81.19%
-0.30 %-54.70%
-0.66 %+12.04%
-0.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

Net Profit Margin of Savior Lifetec is 44.72 % in 2025.

Net Profit Margin of Savior Lifetec changed from 14.98 % to 44.72 %, representing a 198.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Savior Lifetec with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Savior Lifetec

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Savior Lifetec